Adeno-associated viruses (AAV) have attracted attention as potential vectors for gene therapy and vaccines against several diseases, including HIV-1 infection. However, the presence of neutralizing antibodies (NAbs) after natural AAV infections inhibits their transfection in re-exposed subjects. To identify candidate AAV vectors for therapeutic or prophylactic HIV vaccines, NAbs against AAV2, AAV5 and AAV8 were screened in the sera of healthy individuals in China and 10 developed countries and an HIV-1-infected Chinese population. Seroprevalence was higher for AAV2 (96.6%) and AAV8 (82.0%) than for AAV5 (40.2%) in normal Chinese subjects. Among individuals seropositive for AAV5, >80% had low NAb titers (o 1:90). The prevalence and titers of NAbs against the three AAVs were significantly higher in China than in developed countries (Po 0.01). The prevalence of NAbs against AAV5 did not differ significantly between healthy and HIV-1-infected Chinese subjects (P = 0.39). Co-occurrence of NAbs against AAV2, AAV5, and AAV8 was observed in the healthy population, and 15, 41, and 41% of individuals were AAV2 + , AAV2 
INTRODUCTION
Adeno-associated viruses (AAVs) are small, non-enveloped, singlestranded, DNA viruses that require helper viruses to facilitate their efficient replication. 1 A number of unique properties make the AAVs very promising vectors for human gene therapy and vaccines, including a lack of pathogenicity, low immunogenicity and the capacity for long-term gene expression in a wide range of cells. 2, 3 Several AAV-based gene transfer vectors have been developed and tested in clinical studies in recent years, including for the treatment of HIV. 4, 5 A study of the immunogenicity of AAV serotypes showed that the AAV1, AAV5, AAV7 and AAV8 vectors expressing the Env gp160 gene induced higher HIVspecific humoral and cell-mediated immune responses than the AAV2 vector and that the AAV5 vector produced the best responses. 6 However, the initial enthusiasm for AAV vectors diminished when it became apparent that successful gene delivery using AAV vectors might be difficult in humans previously exposed to the same AAV type. 7 For example, an inverse correlation was reported between the preexisting neutralizing antibody (NAb) titer and AAV-based HIV vaccine efficacy. 8 Even very low titers of NAbs (1:5-1:10) completely abrogated transfection with high titers of AAV vectors. [9] [10] [11] Therefore, it is necessary to determine the prevalence of AAV NAbs in potential subjects before the administration of AAV-vector-based products.
A series of enzyme-activated chemiluminescence-based NAb detection tests have been developed, including those based on firefly luciferase (Fluc) 12, 13 and β-galactosidase. 14 Green fluorescent protein has also been used widely as a reporter gene in transgene expression inhibition assays. 15 Until now, the highest frequencies of NAbs have been reported by several groups to be directed against AAV2 (up to 90%) among humans from different countries around the world. 16 Recently, the AAV5 and AAV8 serotypes have emerged as interesting candidates for gene therapies and are structurally and functionally different from AAV2. 17, 18 NAbs directed against these two serotypes have been less frequently studied and occur at lower frequencies, in the range of o10% to 50%.
14 Until now, several AAV candidates, including AAV1, AAV2, AAV5 and AAV8, have been used as vectors for gene therapy, including in an HIV vaccine in China. [19] [20] [21] [22] Therefore, the prevalence of these AAVs in normal subjects and the HIV-1-infected population in China must be investigated urgently if we are to establish clinical guidelines for recombinant AAV-based products.
Our group previously reported the high prevalence of AAV1 NAbs (69.8%) at a dilution of 1:10 in healthy individuals in China, 23 but no data are available for the prevalence of NAbs directed against AAV2, AAV5 or AAV8 in China. Here, a series of Fluc-based neutralization assays was established to investigate the baseline levels of NAbs against AAV2, AAV5 and AAV8 among representative Chinese subjects, including normal blood donors and children undergoing routine physical examination, and to compare them with the frequencies of AAV NAbs in sera from developed countries and an HIV-1-infected population. This could guide the 1 development and administration of AAV-vector-based products, including therapeutic and prophylactic HIV vaccines.
The AAV capsid is the sole antigen shared by both the wild-type virus and AAV vectors and is susceptible to antibody-mediated neutralization. 8 The AAV2/5 and AAV2/8 vectors were constructed by cross-packaging an AAV2 genome into the AAV5 or AAV8 capsid, respectively. The pseudotyped AAV2/5 and AAV2/8 vectors had the same host ranges as AAV5 and AAV8. 24 Therefore, in this study, these two pseudotyped vectors (rAAV2/5-Fluc and rAAV2/8-Fluc) together with rAAV2/2-Fluc (nonpseudotype) were used to quantify the NAbs directed against different AAVs in sera.
RESULTS
Validation of neutralization assays with sera from mice inoculated with four kinds of AAV vectors To standardize the rAAV2/2-, rAAV2/5-and rAAV2/8-Fluc neutralization assays, sera from BALB/c mice vaccinated once with AAV2/1, AAV2/2, AAV2/5 or AAV2/8 virus or saline were used. The mice were monitored for serum NAbs against AAV2, AAV5 or AAV8 following the administration of the different AAV vectors. To allow a comparison of the results for the different AAV vectors, the same amount of virus (3000 viral genomes (vg) per cell) was used in the three neutralization assays. The neutralizing activity in each assay was only detected with sera from homologous-AAVvaccinated mice, with a 50% neutralization titer of 6354 ± 5274, 2312 ± 878 and 1362 ± 971, respectively, whereas the sera from both naive and heterologous-AAV-vaccinated mice showed no significant neutralizing activity (Figures 1a-c) . In all three assays, the development of NAbs was dose dependent, with higher levels in mice that received a higher AAV dose (5 × 10 11 vg) and the lower levels in those that received lower virus dose (5 × 10 10 vg). Taken together, these data show that AAV-serotype-specific NAbs can be detected with the assays developed, with good specificity and sensitivity.
Seroprevalence of anti-AAV NAbs in healthy human samples from China Sera were judged positive for neutralizing capacity when a 1:10 dilution of serum inhibited vector transfection by ⩾ 50%. Generally, the overall percentage of people with detectable NAbs against AAV2, AAV5 and AAV8 were 96.6% (483/500), 40.2% (201/500) and 82.0% (410/500), respectively, in normal individuals from the Beijing and Anhui Provinces. However, there was a significant difference in the prevalence of NAbs against the three AAVs (Po0.01; Figure 2a) . At a serum dilution of >1:80, the prevalence of NAbs to AAV2 (89.4%) was the highest and that to AAV5 (8.6%) was the lowest. Interestingly, the distribution of donors with high titers (>1:810) was the highest for AAV2 (78%), which was also the serotype for which the highest seroprevalence was observed. The majority of individuals who were seropositive for AAV8 (48%) or AAV5 (81%) presented medium (1:90-1:810) or low titers (1:10-1:90), respectively ( Figure 2b ). This indicates that the average NAb titer against AAV5 was much lower than the titers of NAbs against the other two AAVs in all positive individuals (Po0.01). The NAb titer was determined in four different age-related cohorts that covered the birth dates from before 1960 to after 2000. Interestingly, only the percentage of positive NAbs to AAV8 (50% neutralization titer >10) in teenagers (age o 18 years, as of 2013) was significantly lower than that of the adults (19-56 years, as of 2013) at 67.6% and 83.2%, respectively (P = 0.018; Table 1 ).
However, the percentage of positive NAbs against AAV8 did not increase significantly with age in the adults, in the range of 83.2% to 80.9% to 86.2% in the three sequential adult cohorts (P = 0.382). No differences were observed in the prevalence of NAbs against AAV2 and AAV5 by age range (P = 0.236 and 0.965, respectively).
A statistical comparison of the prevalence of NAb activity in the subgroups defined by sex and geographic origin was made and showed that the prevalence of antibodies against AAV5 and AAV8 was significantly higher in women than in men (P = 0.048 and 0.036, respectively). Moreover, higher proportions of sera collected from the Anhui Blood Center had antibodies directed against AAV5 and AAV8 than sera collected from the Beijing Blood Center and hospital (P = 0.011 and 0.001, respectively).
Comparison of anti-AAV NAbs in China and developed countries
In all, the seroprevalence of AAV2, AAV5 and AAV8 NAbs in China were significantly higher than those in developed countries, with the most dramatic differences for AAV8 NAbs (the only exception was the seroprevalence of AAV5 NAbs at a dilution of 1:80; P = 0.50; Figures 3a-c). In terms of the distributions of AAV NAb titers, only AAV2 NAbs differed significantly between China and developed countries (P o 0.01; Figure 3d ). Most AAV2 NAb titers were high (>1:810) in China, but only low titers (1:10-1:90) were observed in developed countries, suggesting a lower average AAV2 NAb titer in those countries. However, the distribution patterns of the NAb titers directed against both AAV5 and AAV8 were very similar in subjects from China and developed countries (P = 0.31 and 0.45, respectively; Figures 3e-f), although significant differences were found in the prevalence of AAV5 and AAV8 NAbs.
Co-occurrence of NAbs directed against AAVs
The co-occurrence of NAbs against AAV2, AAV5 and AAV8 in China and developed countries is shown in Table 2 . In general, there were no sera monospecific for AAV5 or AAV8, and all the sera with neutralizing activity against AAV5 were also positive for AAV2 or The titers (AAV2-, AAV5-and AAV8-neutralizing activities) were determined using the neutralization assay described in Materials and methods. Sera with NAbs titer ⩾ 1:10 were defined as positive. b Significance calculated using the χ 2 test (P-values). AAV8 NAbs, and all individuals with neutralizing activity for AAV8 were positive for NAbs against AAV2. In China, all 37 children o 18 years of age had neutralizing activity against AAV2, and of these children, 15 were also positive for Nabs against AAV5 and 25 were positive for Nabs against AAV8. Of the 463 adults tested, 447 were positive for AAV2 Nabs, and of these, 188 were also positive for AAV5 NAbs and 386 for AAV8 NAbs. The co-occurrence rate was higher in adults than in children (83.3% vs 67.6%, respectively; P = 0.016). There was also a significant difference in the co-occurrence rate by sex (P o0.01) and geographic origin (P o 0.01). In total, 411 of the 484 positive sera (84.9%) from normal individuals showed the presence of NAbs against another AAV serotype. Notably, only 3% of the tested population was seronegative for all of these serotypes. Interestingly, no similar findings emerged from the analysis of samples from 10 developed countries, which showed relatively lower proportions of subjects seroreactivity for the three AAV NAbs (44.4%, 24 of the 54 positive sera). The percentages of the populations seronegative for all AAVs had a range up to 12%.
Seroprevalence of anti-AAV5 NAbs in HIV-1-infected samples from China To determine whether AAV5 could be used as an ideal therapeutic HIV vaccine vector in China, 270 subjects infected with HIV-1 were screened for the seroprevalence of NAbs against AAV5. After correction for multiple comparisons, no significant differences were detected in the seroprevalence of AAV5 NAbs between the healthy individuals and an HIV-1 infected population at serum dilutions of 1:10 (40.6% vs 37.0%; P = 0.39) or 1:80 (8.6% vs 4.8%; P = 0.06) (Figure 4a ). Moreover, there was no difference in the distributions of the AAV5 NAb titers of the two populations, and most of the anti-AAV5 NAb titers in each group were o1:90: (82% for the healthy group and 88% for the HIV-1-infected group; P = 0.19; Figure 4b ). The samples from the HIV-1-infected population were further stratified into four subgroups: intravenous drug users (33 samples), men who have sex with men (130), former commercial plasma donors (47), and those infected by heterosexual transmission (60). The seroprevalence of AAV5 NAbs was determined for serum dilutions of 1:10 and 1:80 (Figure 4c ). The highest seroprevalence at dilutions of 1:10 and 1:80 were found in the intravenous drug users and former commercial plasma donors subgroups, respectively. However, the differences between the different subgroups, corrected for multiple comparisons, were not statistically significant at dilutions of 1:10 and 1:80 (P = 0.31 and 0.35, respectively). The prevalence of anti-AAV5 NAb activity in the subgroups defined by sex or geographic origin was also compared. These data suggest that the prevalence of AAV5 NAbs was not significantly different between HIV-1-infected women and men at dilutions of 1:10 and 1:80 (P = 0.93 and 0.22, respectively). There were no statistically significantly differences between sera from Beijing, Henan and Guangxi Provinces at dilutions of 1:10 and 1:80 (P = 0.23 and 0.11, respectively). Table 2 . Co-occurrence of neutralizing antibodies against AAV2, AAV5 and AAV8
Seropositivity
Number of subjects with the indicated seropositivity 
DISCUSSION
In this study, we characterized for the first time the preexisting humoral responses to the AAV2, AAV5 and AAV8 capsids in healthy Chinese subjects and several populations infected with HIV-1. To this end, a series of AAV-neutralization assays was established, based on inhibiting the infection of 293FT cells by different recombinant AAVs that carried a firefly luciferase gene, with the consequent inhibition of transgene expression. A quantitative analysis using the assay was supported by data showing that the number of rAAV-Fluc particles bound to the cells is directly proportional to the expression of the transgene. 25 Because no human anti-AAV2, -AAV5 or -AAV8 control sera were available, the established neutralization assays were validated with sera from mice inoculated with the AAV1, AAV2, AAV5 or AAV8 vectors. The rAAV-Fluc neutralization assays described here detected the specific NAbs elicited by the homologous AAV vector, and no cross-reactivity with heterologous NAbs was observed. It was important that the assays should be done under conditions of antibody excess to maximize their sensitivity and to allow a comparison of the different AAV vectors to be made. Our group previously used an AAV1-neutralizing assay to show a direct correlation between the rAAV2/1-Fluc virus concentration of 1563-200 000 vg per cell and reporter transgene expression. 23 Because of the low infectivity of the AAV5 vector, a 3000 vg per cell ratio (bottom of the linear range) was chosen as the optimal viral infective dose to allow accurate and comparable determinations of vector titers for all the vectors. Similarly, most researchers have selected doses of 1000-10 000 vg per cell for NAbs against AAV2, AAV5 or AAV8, 8, 14, 26 which allow parallel comparisons between different studies. It has been demonstrated that T-and B-cell activation was significantly diminished by human sera with no detectable NAbs (initial dilution, 1:20) in the sera of passively transferred mice. 8 In this study, the in vitro AAV NAb assays were optimized with an initial dilution of 1:10, which was sufficiently sensitive to detect NAb levels capable of interfering with the performance of the vector in vivo.
In this study, the prevalence and potency of AAV2-, AAV5-and AAV8-specific NAbs were investigated with human samples from different geographic regions in China and compared with samples from developed countries around the world. We demonstrated that the prevalence of anti-AAV2 NAbs was significantly higher than that of anti-AAV5 or anti-AAV8 antibodies in China and developed countries. The prevalence and titers of AAV2, AAV5 and AAV8 NAbs in China were also significantly higher than those in developed countries. Antibodies directed against AAV8 are expected to have lower seroprevalence among humans than among nonhuman primates, which was observed in France in only 19%. 12 Although the seroprevalence of antibodies directed against AAV8 was lower than that of anti-AAV2 antibodies, it was still much higher than the seroprevalence of anti-AAV5 antibodies (82.0% vs 40.2%, respectively). A similar frequency (about 90%) of NAbs against AAV8 was described previously in healthy donors in the Netherlands with an AAV8-green fluorescent protein assay. It was noteworthy than a higher prevalence of NAbs against AAV5 (78%) was shown in the same population. 15 However, this result did not corroborate the results of subject screening in America and France, which indicated that only 30-59% of adults were seropositive for AAV2, and o10-20% were seropositive for AAV5 when AAV-Luc or AAV-alkaline phosphatase was used. 12, 26, 27 In the present study, a correlation was observed between the prevalence of NAbs against a specific AAV type and the distribution of titers, which is consistent with the observation that most samples positive for AAV5 (98.7%) usually showed a low titer of NAbs in the Netherlands. 15 Overall, the prevalence of AAV2-, AAV5-and AAV8-specific NAbs in China was significantly higher than those in developed countries. This phenomenon may be related to the different levels of health care available in various countries.
Interestingly, we found significant differences in prevalence according to sex, age range and geographic origin in the Chinese subjects. The relatively lower incidence of AAV8-neutralizing activity throughout childhood was encouraging, because it provides a wide window of opportunity for vaccination and gene therapy with an AAV8 vector. We attribute the increase with age to changes in the social behavior of individuals after the age of 18 years, because when they move outdoors and have increased contact with others, their chance of exposure to wild-type AAV8 increases. The markedly higher frequencies of NAbs directed against AAV5 and AAV8 observed in Anhui relative to those in Beijing were surprising. In the absence of clear demographic correlates with the data, it remains unclear whether living conditions, major histocompatibility complex status or other factors are involved in this phenomenon.
The prevalence and titers of AAV5-specific NAbs were also analyzed in an HIV-1-infected population to evaluate the possible application of AAV5 as a therapeutic vaccine vector in China. In total, 270 sera were sampled from the four main HIV-1-infected populations in China: intravenous drug users, men who have sex with men, former commercial plasma donors, and heterosexual transmission. Sera of different geographic origins were obtained from three different provinces, Beijing (north), Henan (middle) and Guangxi (south). Therefore, the prevalence characteristics of AAV5 NAbs are representative of China. The prevalence of AAV5 NAbs was much lower than that of AAV2 or AAV8 NAbs, which supports the possible use of AAV5 for the production of a therapeutic HIV-1 vaccine.
The co-occurrence of NAbs directed against AAV2, AAV5 and AAV8 may be the result of multiple or coinfections within the same individual. As shown, all individuals positive for NAbs against AAV5 or AAV8 also had NAbs against AAV2. Moreover, the AAV2 titer was the highest in all the sera with neutralizing activity for more than one AAV. We consider that AAV2 may be more immunogenic, stimulating a more robust neutralizing response than AAV5 or AAV8. Another hypothesis explaining these results is that humans generate a serological response of greater breadth, which may be attributable to the rapid molecular evolution of multiple coinfecting parental viruses and could lead to the generation of antibodies directed against a wide spectrum of antigens. 28 As is well known, the high prevalence of human serum antibodies directed against AAV vectors can disrupt the development of capsid antibodies during primary exposure, which represents a potential limitation to the use of these vectors in vivo. A strategy used by a number of groups is to alter the AAVneutralizing epitopes by mutating the viral capsid, thereby reducing the antibody affinity for the vector. 29, 30 Alternatively, this study suggests that the neutralizing capsid antibodies against one serotype did not cross-react with the other serotypes, allowing the sequential transfection of alternative serotypes. 17 Riviere demonstrated that the cross-administration of rAAV1, rAAV2 and rAAV5 is a very efficient approach to gene transfer into the skeletal muscle. 31, 32 The covalent attachment of polyethylene glycol (PEG) to the surface (PEGylation) of AAV had also been used successfully to shield the virus from NAbs in vitro and in vivo without substantial loss of infectivity. 33 In summary, we have shown that the majority of healthy and HIV-1-infected individuals examined were positive for Nabs against AAV2 and AAV8. The prevalence and strength of the antibodies indicated that the AAV5 vector would be most useful for evading the AAV-acquired immune response during gene therapy or vaccination in China. The lack of cross-reactivity between AAV serotypes should promote the use of one of these serotypes as an alternative to another to allow their readministration to naive recipients. 
rAAV-Fluc viruses
Three kinds of pseudoviruses, rAAV2/2-Fluc, rAAV2/5-Fluc and rAAV2/8 -Fluc, were generated as described previously 22 by Dr Xiaoyan Dong at the Beijing FivePlus Molecular Medicine Institute. In brief, pAAV2neo was obtained by inserting a fragment containing two inverted terminal repeats from AAV2, the cytomegalovirus (CMV) promoter, multicloning sites and BGH polyA into pSV2neo. pAAV2neo-Fluc was then constructed by inserting the gene encoding Fluc between the CMV promoter and BGH polyA. The rAAV-vector-expressing cell lines were obtained by transfecting BHK21 cells with pAAV2neo-Fluc and culturing them in the presence of 800 μg ml − 1 G418 for 2 weeks. Recombinant herpes simplex virus type 1 carrying the AAV2 rep and AAV5 or other serotype cap gene (rHSV1-UL2/ rep2cap5 or rHSV1-UL2/rep2cap8) was then used to provide the helper functions for packaging the different AAV vectors. Finally, two rAAV-Fluc vectors were produced by infecting the AAV vector cell line with rHSV1-UL2/rep2cap5 or rHSV1-UL2/rep2cap8 at a multiplicity of infection of 1-5. After 48-72 h, the infected cells were harvested and purified. The rAAV titers were determined by dot blotting using a digoxin-labeled CMV promoter fragment as the probe.
AAV virus antisera
Fifty BALB/c mice were divided into five groups (n = 10), and each group of animals was inoculated once intramuscularly with one of four AAVs (AAV serotype 1, 2, 5 or 8), at a dose of 5 × 10 10 vg (n = 5) or 5 × 10 11 vg (n = 5). Fifty-five-week-old specific-pathogen-free BALB/c mice were obtained from the National Institutes for Food and Drug Control (NIFDC), Beijing, China. Before inoculation, all the animals were confirmed to be negative for NAbs against the different AAVs. The animals were handled according to the National Guidelines for the Care and Use of Medical Laboratory Animals.
Human serum samples
The study was conducted after receiving approval from the Ethical Committee for the research. Informed consent, and assent if applicable, was obtained from all the subjects. Normal subjects in China, including blood donors and children undergoing a routine physical examination, were recruited from the Beijing Blood Center (200 samples; Beijing), the General Hospital of the Air Force (100 samples; Beijing) and Anhui Blood Center (200 samples; Hefei). Human serum samples from 500 subjects (278 men, 222 women) with an age range from o18 to 56 years (as of 2013) were obtained from a diverse human population of healthy individuals, with no known previous exposure to AAV2, AAV5 or AAV8. Sixty-one individuals (43 men, 18 women), with an age range from 21 to 74 years (as of 2013) from 10 different developed countries, who had just come to live in China for o1 month, also participated in this study. Twenty-eight individuals were from the Unites States, eight from the Ukraine, six from England, five from France, three from Italy, three from Russia, two from Germany, two from Austria, two from Canada and two from Spain. A total of 270 subjects infected with HIV-1 (207 men, 63 women), with an age range of 5-64 years (as of 2013), were recruited from Beijing, Guangxi and Henan Provinces to investigate the prevalence of AAV5-specific NAbs. Thirty-three subjects were intravenous drug users, 130 were men who have sex with men, 47 were former commercial plasma donors and 60 were infected by heterosexual transmission. All samples were frozen at -80°C and banked at the institutions after collection. The samples were shipped on dry ice to the NIFDC. All samples were thawed, aliquoted and stored at -80°C until assay. Before the neutralizing assays were performed, the serum samples were heat inactivated at 56°C for 1 h, and then stored at 4°C.
Fluc-based neutralizing assay
Neutralization was measured as the reduction in Fluc reporter gene expression from rAAV-Fluc when inhibited by the NAbs against AAV2, AAV5 or AAV8 present in the serum samples. Vg of rAAV2/2-Fluc, rAAV2/5-Fluc or rAAV2/8-Fluc (5 × 10 7 vg in 50 μl of Dulbecco's modified Eagle's medium containing 10% fetal bovine serum) were mixed with 100 μl of serum diluted with the same medium to achieve final serum dilutions of 1:10, 1:30, 1:90, 1:270 and 1:810 or incubated without serum as the control. The neutralizing effects of human serum diluted o 1:10 were not examined to avoid any nonspecific inhibition of transfection. One hour after incubation, a trypsinized single-cell suspension of 15 000 293FT cells was added to 100 μl of medium. The plates were then placed on a plate shaker for 10 s and incubated at 37°C under 5% CO 2 for up to 24 h. After incubation, 150 μl of supernatant was aspirated and 100 μl of D-luciferin substrate containing the lysis reagent for the 293FT cells (Caliper, Hopkinton, MA, USA) was added to each well while protected from light and incubated at room temperature for 2 min. Luminescence was then measured in 100 μl of the lysis mixture, using a GLOMAX 96 microplate luminometer (Promega, Madison, WI, USA). For each AAV NAb assay, anti-AAV mouse serum was used as the reference to establish in-house standard serum samples, whereas pooled serum samples from preimmune mouse sera were used as the negative controls.
The 50% neutralization titer for each serum sample was defined as the serum dilution at which the relative light units were reduced by 50% compared with those for virus-containing control wells after subtraction of the background relative light units in the cell-containing control wells. Titers of ⩾ 1:10 were considered positive. The serum was further categorized as having a low, medium or high titer if a ⩾ 50% reduction in vector transfection was achieved with o 1:90, 1:90-1:810 or >1:810 dilutions, respectively.
Statistical analysis
The results are expressed as means ± s.d., and data are summarized as graphical displays and descriptive statistics (that is, counts and proportions for categorical variables). The AAV seroprevalence in different groups was compared with the χ 2 test. Where indicated, a logistic regression model was used for covariate adjustment when evaluating potential associations. Graphs were plotted with GraphPad Prism 5.0 (GraphPad Software, San Diego, CA, USA), and statistical analyses were computed with SPSS (ver. 18.0; IBM, Armonk, NY, USA). A P-value of o0.05 was considered statistically significant.
